Bcl-2 has been shown to promote survival of cancer cells by maintaining a slight pro-oxidant state through elevated mitochondrial respiration during basal conditions. On oxidative stress, Bcl-2 moderates mitochondrial respiration through cytochrome c oxidase (COX) activity to prevent an excessive buildup of reactive oxygen species (ROS) by-production from electron transport activities. However, the underlying molecular mechanism(s) of Bcl-2-mediated ROS regulation and its impact on carcinogenesis remain unclear. In this study, we show that Bcl-2 expression positively influences the targeting of nuclearencoded COX Va and Vb to the mitochondria of cancer cells. In addition, evidence is presented in support of a protein-protein interaction between COX Va and Bcl-2, involving the BH2 domain of Bcl-2. Interestingly, episodes of serum withdrawal, glucose deprivation or hypoxia aimed at inducing early oxidative stress triggered Bcl-2-overexpressing cells to preserve mitochondrial levels of COX Va while depressing COX Vb, whereas the reverse was observed in mock-transfected cells. The unique manner in which Bcl-2 adjusted COX subunits during these physiological stress triggers had a profound impact on the resultant decrease in COX activity and maintenance of mitochondrial ROS levels, thus delineating a novel mechanism for the homeostatic role of Bcl-2 in the redox biology and metabolism of cancer cells.
Introduction
The onset and maintenance of the cancer phenotype is orchestrated by a combination of dysregulated cellular pathways that contribute to a resistant environment favorable for cancer cells to thrive in. Recent literature has expounded on the intricate controls behind cancer metabolism, ranging from the emerging nontranscriptional role of p53 to the expanding reach of HIF-1 involvement in the field.
1,2 Despite their multiple roles, the stark similarity lies in their connection to cytochrome c oxidase (COX) and its regulation, signaling the dawn of the Warburg effect-revisited era.
Cytochrome c oxidase is the terminal complex of the electron transport chain and is located in the inner mitochondrial membrane. COX exists as a dimer, consisting of 13-subunit monomers. The core subunits of COX (subunits I, II and III) are encoded by the mitochondrial genome. The remaining 10 subunits are encoded by the nuclear genome. The nuclear-encoded subunits that surround the catalytic core of COX were shown to be involved in the assembly, stability and dimerization of the enzyme. 3, 4 In yeast, the expression of COX IV and VI was shown to be aerobically regulated, whereby the amount of fully assembled COX decreases with decreasing oxygen concentration. [5] [6] [7] [8] In the mammalian system, these COX subunits are designated as COX Vb and Va, respectively. During the assembly of COX in mammalian cells, COX Va is incorporated, followed by COX Vb, suggesting that COX Va may determine the integration of COX Vb and that the subsequent addition of COX Vb may have a vital role in COX enzymatic activity. 9, 10 Interestingly, recent studies have demonstrated an upregulation and an increased involvement of COX Va and Vb in a variety of cancers, such as colorectal cancer, squamous cell cancer of the larynx, intraductal carcinoma of the breast and prostate cancer. [11] [12] [13] [14] [15] [16] In addition, upregulation of COX Vb has been observed in energy-demanding cell types and healthy tissues; is shown to inhibit apoptosis in intestinal epithelial cells; and is associated with an increase in COX activity in cervical (HeLa) and lung carcinoma cells (A549). 12, 17, 18 Although the precise regulatory mechanisms and functional roles of these COX subunits in oncogenesis have yet to be elucidated, extensive studies from their yeast homologs, as well as their physiological roles in normal mammalian cells, may suggest similar functions in the mitochondria of cancer cells by enhancing the availability and stability of the final enzyme, thus exerting profound effects on the resultant activity. COX activity influences the overall rates of mitochondrial respiration and electron transport, processes that are not completely efficient, resulting in the generation of superoxide (O 2 À ) as a by-product and creating a pro-oxidant milieu to facilitate an extensive array of downstream reactive oxygen species (ROS)-mediated signaling pathways. [19] [20] [21] Bcl-2 is an anti-apoptotic protein, first discovered as a reciprocal gene translocation in chromosome 14 and 18 of follicular lymphomas. Its main site of action and localization lies on the outer mitochondrial membrane and its protective mechanisms center on preserving mitochondrial membrane integrity, preventing cytochrome c release and sequestrating pro-apoptotic proteins such as Bax and Bak. 22, 23 We previously reported that overexpression of Bcl-2 was associated with a slight increase in intracellular O 2 À production, and reduction of O 2 À sensitized Bcl-2-overexpressing cells to apoptotic stimuli. 20 More recently, we reported a novel, noncanonical role of Bcl-2 in amplifying mitochondrial respiration and COX activity in tumor cells, which is linked to the slight pro-oxidant activity of Bcl-2. 19, 20, 24, 25 Intriguingly, Bcl-2 has also been shown to maintain the slight pro-oxidant state during periods of stress through metabolic adaptations by regulating COX activity and mitochondrial respiration, suggesting a novel anti-apoptotic role of Bcl-2 in conferring resistance to cancer cells. 25 In this study, we tested the hypothesis that Bcl-2 regulation of COX activity was mediated by COX Va and Vb. Indeed, we report an increase in COX Va and Vb localization in the mitochondria of Bcl-2-overexpressing CEM cells during normal conditions and alterations in the composition of these subunits within the mitochondria during bouts of oxidative stress.
Results

Bcl-2 increases O 2
À production through increased mitochondrial respiration in cancer cells. Similar to our earlier reports, we detected consistently higher levels of intracellular O 2 À in Bcl-2-overexpressing CEM cells (1.27 ± 0.08-fold) compared with CEM/Neo cells (Figure 1a) . Similarly, using a fluorescent probe for mitochondrial O 2 À (MitoSOX), higher levels of O 2 À were detected in the mitochondria of CEM/Bcl-2 cells compared with CEM/Neo cells, which was corroborated by the lucigenin-based assay performed on isolated mitochondria from both cell lines (Bcl-24 Neo by 1.71 ± 0.01-fold) (Figure 1b, c) . In agreement with our recent findings, CEM/Bcl-2 cells showed a higher COX activity than did CEM/Neo cells by 2.49 ± 1.04-fold, suggesting that mitochondrial respiration could be involved in the pro-oxidant state of Bcl-2-overexpressing cells (Figure 1d) . The relationship between mitochondrial O 2 À production and mitochondrial respiration has also been shown in HeLa cells from our previous study 25 (Supplementary Figure  S1a, b) . To ascertain that our observation was not exclusive to CEM cells, we tested our hypothesis in three other cancer cell lines, namely HK-1 and C666-1 (nasopharyngeal carcinoma) and HCT116 colorectal carcinoma. It is noteworthy that the levels of Bcl-2 expressed in the respective cell lines corresponded with levels of mitochondrial O 2 À (HK-1, 227.5±10.6 relative light units (RLUs)/s per mg protein; C666-1, 17.5 ± 3.54 RLU/s per mg protein; HCT116, 115 ± 49.5 RLU/s per mg protein) and COX activity (HK-1, 1; C666-1, 0.20±0.16; HCT116, 0.24±0.04) (Figure 1e-g ). There was no significant difference in citrate synthase activity in all three cell lines (Supplementary Figure S4b) . These data provide strong evidence that the effect by Bcl-2 overexpression on mitochondrial respiration and COX activity was not a function of enforced expression, but indeed a true reflection of the effect of Bcl-2 on mitochondrial physiology.
Bcl-2 interacts with the nuclear-encoded subunit Va of COX. Having established the fact that Bcl-2 expression resulted in increased COX activity and mitochondrial respiration, we investigated the possibility of a physical association between Bcl-2 and COX. Using DaliLite Pairwise comparison software (www.ebi.ac.uk/DaliLite/), human Bcl-2 was compared against all subunits of bovine COX enzyme on the basis of structures available from PDB. Of the 13 COX subunits, only COX Va produced a significant z-score, suggesting a structural homology between the two proteins ( Figure 2a ). Despite considerable primary structural differences between bovine and human COX Va, further analysis using BLAST revealed that the region of COX Va bearing a structural homology with Bcl-2 was conserved in both species. Using this information, coimmunoprecipitation studies were performed. A protein-protein interaction was identified between Bcl-2 and COX Va but not with COX Vb (Figure 2b A high Bcl-2 expression leads to an enhanced localization of COX Va to the mitochondria without affecting its expression. To delineate the functional relevance of Bcl-2 interaction with COX Va, isolation of intact mitochondria and subfractionation into its inner mitochondrial fraction were carried out using 20 mg/ml proteinase K to remove the outer mitochondrial membrane. Localization of COX Va in the whole mitochondria and inner mitochondrial fractions was enhanced in CEM/Bcl-2 cells when compared with CEM/Neo cells (Figure 3a, Supplementary Figure S6a) . Fractionation of CEM cells into respective subcellular components revealed an increased localization of COX Va in the mitochondria over the nuclear fraction in CEM/Bcl-2 cells (Figure 3a) . The reverse was observed in CEM/Neo cells (Figure 3a) . Differences in the localization of COX Va observed by western blot analysis were correspondingly quantified by densitometry analysis (Figure 3a) . Serendipitously, overexpression of Bcl-2 also resulted in an improved localization of COX Vb into the inner mitochondria of these cells (Figure 3a ). An increased localization of COX Vb into the inner mitochondria may have an unprecedented role in regulating COX activity, thus contributing to a pro-oxidant state in CEM/Bcl-2 cells during normal conditions. More importantly, Bcl-2 overexpressionmediated COX activity was not a function of changing COX Va and Vb expression but that of improved targeting of nuclear-encoded mitochondrial proteins (Figure 3a , Supplementary Figure S6a ).
To verify our mitochondrial isolation technique, we repeated the experiment this time using an established protocol for the isolation of mitochondria. 26 Again, COX Va was more prominently localized to the mitochondria of Bcl-2-overexpressing CEM cells (Supplementary Figure S2a) . Furthermore, to ensure that our mitochondrial fractions were free from cytosolic contamination, we loaded increasing amounts of mitochondrial proteins and did not detect a corresponding increase in CuZn SOD, a faithful cytosolic protein marker, compared with COX Va and prohibitin (Supplementary Figure S2b) .
Transient overexpression and knockdown of Bcl-2 by siRNA were performed to investigate whether the phenomenon observed in CEM/Neo and CEM/Bcl-2 cells could be reversed. Indeed, the overexpression of Bcl-2 in CEM cells increased the localization of COX Va from the nucleus to the mitochondria and the silencing of Bcl-2 in CEM/Bcl-2 cells reversed the effect (Figure 3b ). Repeating earlier experiments using HK-1 and C666-1 cells with inherently contrasting levels of Bcl-2 expression corroborated our previous findings with CEM cells (Figure 3c ). Similarly, Bcl-2 silencing with siRNA reverted the observations in HK-1 cells to that akin to C666-1 cells (Figure 3d ). Further reinforcing the role of Bcl-2 in promoting the localization of COX Va to the mitochondria in transformed cells, lymphoma samples from three different patients reaffirmed this aspect of Bcl-2 ( Figure 3e ).
In addition, immunofluorescence confocal microscopy showed the colocalization of COX Va and Bcl-2 ( Figure 3f Taken together, these results reiterate the functional relevance of Bcl-2 interaction with COX Va in terms of promoting COX Va incorporation into the mitochondria. It is plausible that overexpression of Bcl-2 might increase COX activity by improving COX Va distribution to mitochondria without affecting its expression.
Bcl-2 modulates mitochondrial respiration during stress states by stabilizing COX Va and decreasing COX Vb in the mitochondria. To further our understanding of the regulatory role of Bcl-2 in mitochondrial respiration and COX activity for the maintenance of redox status in the face of oxidative insults, we subjected CEM/Neo and Bcl-2 cells to physiological stress states aimed at the early induction of oxidative insult. Induction of mitochondrial oxidative stress by 5 mg/ml antimycin for 1 h did not alter the global expression of COX Va and Vb (Figure 4a ).
Interestingly, western blot analysis of isolated inner mitochondria from CEM/Bcl-2 cells treated similarly indicated a slight upregulation of COX Va and a downregulation of COX Vb (Figure 4b ). The reverse was observed in CEM/ Neo cells (Figure 4b) . A combined treatment for 1 h with 20 ng/ml leptomycin B, a nuclear export inhibitor, did not affect the respective observations, but exacerbated the antimycin-treated conditions, suggesting that the nuclear export machinery may not be responsible for the alterations in the targeting of COX subunits to the mitochondria on oxidative stress in CEM cells. Next, CEM/Neo and Bcl-2 cells were subjected to serum deprivation in a dose-dependent manner for 24 h. The respective abbreviations contain the following annotations: IM -inner mitochondria, WM -whole mitochondria, WC -whole cell. COX I, VDAC and actin were probed as control markers for inner mitochondria, whole mitochondria and whole-cell lysate, respectively. (e) Using lymphoma cells from three patient samples, the extent of COX Va localization to the mitochondria was assessed in relation to the respective levels of Bcl-2 expression. VDAC and actin were probed as loading control markers for mitochondria and whole-cell lysate, respectively. (f) Overexpression of Bcl-2, Bcl-2 colocalization with COX Va and COX Va localization patterns were demonstrated using confocal microscopy. (g) Mitochondrial localization of COX Va in CEM/Neo and CEM/Bcl-2 cells was determined by confocal microscopy. Duplicates were performed for CEM/Neo cells in panels f and g whereas the levels of the species were stabilized in their CEM/Bcl-2 counterparts, which could be a function of the downregulation in COX activity (450%) and vice versa in CEM/Neo cells, suggesting that fluctuations in COX Va and Vb distribution within the mitochondria might have a role in defining the level of COX activity (Figure 5b , c, Supplementary Figure S3b, c) . In addition, hypoxia, serum withdrawal and glucose deprivation did not alter the transmembrane potential and mitochondrial ATP production in CEM/Bcl-2 cells (Figure 5d, e) . In contrast, all three conditions resulted in a depolarization of the transmembrane potential and in slight increases in mitochondrial ATP production in CEM/Neo cells (Figure 5d , e). However, untreated and treated CEM/Bcl-2 cells consistently produced more mitochondrial ATP than did CEM/Neo under all conditions (Figure 5e ). The basal mitochondrial transmembrane potential was also slightly higher in CEM/Bcl-2 cells than in CEM/Neo cells (Figure 5d) . Moreover, the effect on COX exerted by these physiological stress conditions did not involve complex I, II, III and citrate synthase (Supplementary Figure S4a, b) .
Bcl-2 interaction with COX Va is predominantly mediated by the BH2 domain and C-terminal region of Bcl-2. Finally, we sought to address the interacting domains of Bcl-2 with COX Va. On the basis of DaliLite Pairwise comparison software and using site-directed mutagenesis, we generated a BH4 domain mutant (R26K), a C-terminal region mutant (A234G) and a BH2 domain mutant harboring a single mutation at the BH2 domain and multiple mutations at its flanking upstream and downstream regions (Figure 6a) . The protein-protein interaction between Bcl-2 and COX Va was significantly reduced in CEM/Neo cells overexpressing the BH2 domain mutant (Figure 6b) . Similarly, the C-terminal region mutant showed a slightly reduced association with COX Va (Figure 6b ). In contrast, mutation at the BH4 domain failed to disrupt Bcl-2 binding to COX Va on the basis of coimmunoprecipitation studies (Figure 6b) . A reduced interaction between C-terminal and BH2 mutants with COX Va resulted in a corresponding decrease in the mitochondrial localization of COX Va and COX activity to the basal levels of CEM/Neo cells, which, in turn, exerted a likely consequential effect on the byproduction of O 2 À through decreased mitochondrial respiration, affecting the overall redox status in these cells (Figure 6b-d 
Serum withdrawal
Glu -2% 0.50% 5% 0.50% Glu + Glu -2% 0.50% 5% 0.50% Glu + Glu -2% 0.50% 5% 0.50% Serum withdrawal Densitometry analysis of the changing levels and ratio of COX Va and Vb in both cell lines during these stress conditions are represented graphically. Bcl-2 was separately probed using whole mitochondria to detect for overexpression before the outer mitochondrial membrane was removed. Actin, COX I and PARP were probed as control markers for whole-cell lysate, inner mitochondria and nucleus, respectively, in panels a-d corresponding O 2 À levels to that of CEM/Bcl-2 cells, suggesting the noninvolvement of the BH4 domain in this unique role of Bcl-2 in regulating mitochondrial respiration through COX activity (Figure 6b-d) . There was no considerable difference in citrate synthase activity to confound our COX activity measurements (Supplementary Figure S4b) .
Discussion
In this study, we showed that Bcl-2-mediated increase in COX activity is due to the enhanced presence of COX Va and Vb in the mitochondria, indicative of a more complete and stable COX enzyme. Our results showed that an increase in mitochondrial Bcl-2 as a result of an intrinsic high expression or overexpression directly promotes the translocation of nuclearencoded COX Va to the mitochondria through a physical interaction, without affecting its expression. The increased presence of mitochondrial COX Va is not due to an increase in the formation of the initial COX intermediate, as the level of mitochondrial-encoded COX I has been shown to be unaffected in Bcl-2-overexpressing tumor cells previously. 25 Indeed, using COX I as a marker, one-dimensional BN-PAGE revealed more partially assembled COX subcomplexes in CEM/Neo compared with CEM/Bcl-2 cells, further confirming the lower amounts of mitochondrial COX Va in cells with a lower Bcl-2 expression (Supplementary Figure S5) . Furthermore, taking into consideration the fact that both Bcl-2 and COX Va are nuclear-encoded, mitochondria-targeted proteins, we propose Bcl-2 as a likely chaperone to COX Va, facilitating its targeting to the mitochondria, resulting in a more inclusive COX, capable of greater enzymatic activity. On the other hand, an increased COX Vb presence in the inner mitochondrial membrane, despite no physical association with Bcl-2, could be a collateral effect of Bcl-2 insertion at the outer mitochondrial membrane and a subsequent alteration of membrane dynamics, allowing more COX Vb to traverse across membranes. Furthermore, the yeast analog of COX Vb, COX IV, has been shown to be post-transcriptionally regulated by the cardiolipin content of the mitochondria. 27 The likelihood of Bcl-2 affecting COX Vb localization to the outer mitochondrial membrane is ruled out, as total COX Vb from the intact mitochondria fraction is the same in CEM/Neo and Bcl-2 cells, suggesting that Bcl-2-mediated COX Vb translocation across mitochondrial membranes may be linked to the enhanced localization of COX Va. One possible explanation would be that COX assembly is a multistep process and COX Va is upstream of COX Vb in the assembly hierarchy; increased COX Va-assembled intermediates may promote the downstream incorporation of COX Vb, which has been harboring at the outer mitochondrial membrane, waiting for translocation into the inner mitochondrial membrane to form COX. Alternatively, Bcl-2 and the yeast homolog COX IV (COX Vb) have also been shown to interact with mitochondrial import protein Tom20 in Saccharomyces cerevisiae, an implication that Bcl-2 may similarly promote the import of COX Vb across mitochondrial membranes through Tom20 in the mammalian system. 28, 29 Increased COX Va and Vb in the inner mitochondrial compartment of high Bcl-2-expressing tumor cells reflects the greater capacity of these cells to carry out oxidative phosphorylation and mitochondrial respiration, encouraging ATP production. In parallel, by-production of O 2 À is augmented, resulting in the pro-oxidant state reported in tumor cells with a high Bcl-2 expression 20, 25 (Figure 7a ). Our study suggests that despite tumor cells preferentially utilizing glycolysis instead of oxidative phosphorylation as the primary source of energy production as postulated by Warburg, antiapoptotic proteins such as Bcl-2 may exert dual functions in its protective role: the first is the canonical inhibition of proapoptotic proteins and the safeguard of mitochondrial membrane integrity to prevent the execution of apoptosis; the second is the nonclassical optimization of mitochondrial respiration and the prevention of the excessive compromise of mitochondrial respiration in tumor cells to boost ATP production and a level of ROS most suited for pro-survival signaling. Indeed, this novel function of Bcl-2 seems to be dependent on its BH2 domain, the mutation of which affects its binding to Bax without affecting its homodimerization, accounting for the death-repressive activity of Bcl-2. 30 This may explain the dominant-negative effect of BH2-mutated Bcl-2 on COX activity over nontransfected control. The overexpression of mutant BH2-Bcl-2, in addition to its ability to inhibit the interaction between COX Va and Bcl-2, may also homodimerize (with the resident Bcl-2) and neutralize any COX Vabinding ability of basal Bcl-2. In the absence of Bcl-2, tumor cells rely predominantly on glycolysis for energy and inhibit mitochondrial functions to a level below that of normal cells to prevent the onset of the death programme. Thus, it is conceivable that cancer cells may seek to preserve their mitochondrial functions through this novel role of antiapoptotic Bcl-2 to increase the chances of survival and invasion. The ability of Bcl-2 to fine-tune COX activity by adjusting the distribution of COX Va and Vb in the mitochondria throughout different stress conditions reflects the importance of the composition of subunits in COX during metabolic reprogramming for cancer cells (Figure 7a ). Many studies have established the expression of yeast homologs COX IV and VI (COX Vb and Va) as being aerobically regulated, whereby the expression is positively correlated to the oxygen content. [5] [6] [7] [8] Furthermore, yeast COX VI is repressed by glucose. 31, 32 In this respect, our results indicate that regulation of COX subunits during metabolic adaptation may be controlled by oncoproteins such as Bcl-2. During hypoxia, overexpression of Bcl-2 stabilized COX Va and reduced the COX Vb mitochondrial presence, whereas the reverse was detected in the absence of Bcl-2 overexpression. These cells responded similarly under a glucose-deprived condition. In light of this, we demonstrated for the first time that adaptations in tumor metabolism are intrinsically different from physiological adaptations in the yeast model in response to oxygen and glucose tensions, further distinguished by the ability of Bcl-2 to alter the responses of COX Va to oxygen and glucose.
In addition, our results suggest that during oxidative stress, COX Vb may replace COX Va in increasing COX activity, whereas COX Va may have a regulatory role in keeping COX activity in check. This is evident from our observation that on oxidative stress, lack of COX Va in the presence of COX Vb resulted in a significant upregulation of COX activity in CEM/ Neo cells, whereas the stable presence of COX Va in the absence of COX Vb resulted in the downregulation of COX activity in CEM/Bcl-2 cells. This is in addition to the role that COX Va has during normal conditions in which increased mitochondrial COX Va leads to higher COX activity. Collectively, these results suggest that COX subunits may exhibit interchangeable roles to determine COX activity, depending on the microenvironment of tumor cells; and Bcl-2 may be central to this regulation (Figure 7a, b) . Our study highlights the importance of the regulation behind the incorporation of these subunits to form COX and the resultant impact on COX activity during basal tumor metabolism and adjustments to oxidative stress. Downregulation of mitochondrial respiration and maintenance of mitochondrial O 2 À production in the face of potentially deleterious conditions reflect the plasticity of tumor metabolism, fine-tuned by Bcl-2 with respect to COX. Cancer cells are often saddled with various stress conditions, and this may reflect a novel function of Bcl-2 in aiding these cells to overcome the treacherous barriers faced during metastasis, while maintaining the redox milieu and energy production necessary for survival. A more important implication in terms of cancer therapeutics could suggest that certain tumors with an intrinsically high Bcl-2 expression may render them more refractory to ROS-based treatments compared with other tumors with a low basal Bcl-2 expression, corresponding to better prognosis. In this study, we provide an additional mechanism to Bcl-2-induced chemoresistance through the mitochondrial respiratory pathway, as well as reiterate the importance of Bcl-2-targeted therapies and the significance of COX Va and Vb as cancer markers.
Materials and Methods
Cell culture. CEM human leukemia cells stably transfected with the control vector (CEM/Neo) or Bcl-2 (CEM/Bcl-2) were maintained in RPMI 1640 supplemented with 2 mM L-glutamine, 1% streptomycin-penicillin (v/v) and 5% FBS (v/v). G418 disulfate salt solution was added as a selective antibiotic for the maintenance of stable transfectants. HK-1 and C666-1 cell lines were derived from nasopharyngeal carcinoma, which was maintained in RPMI 1640 supplemented with the constituent mentioned previously and 10% FBS (v/v), without G418 antibiotic. HCT116 is a colon carcinoma cell line maintained in McCoy's 5A medium similarly supplemented as that for HK-1 and C666-1. All cell lines were cultured in a humidified incubator at 371C and 5% CO 2 .
Isolation of nuclear fraction. Cells were harvested and washed with icecold 1 Â PBS and spun down by centrifugation at 1500 Â g for 3 min at 41C. The resultant pellets were resuspended in 400 ml Buffer A (10 mM HEPES, 10 mM KCL, 0.1 mM EDTA and 0.1 mM EGTA at pH 7.9) and were left to swell for 15 min on ice. Thereafter, 25 ml of 10% NP-40 was added before vortexing for 10 s. The insoluble nuclear fraction was collected by centrifugation at 14 000 r.p.m. for 30 s at 41C. The nuclear fraction pellet was further resuspended in 50 ml Buffer C (20 mM HEPES, 0.4 mM NaCl, 1 mM EDTA and 1 mM EGTA at pH 7.9) and rocked vigorously for 15 min at 41C. The resultant supernatant containing the nuclear proteins is obtained by centrifugation at 14000 r.p.m. for 5 min at 41C.
Measurement of mitochondrial ATP. To inhibit glycolytic ATP production, cells were precultured in medium supplemented with 2-deoxy-glucose and 2 mM pyruvate in place of normal glucose on an equimolar basis, before being subjected to various stress conditions. The level of ATP was quantified using the ATP bioluminescent somatic cell assay kit (Sigma-Aldrich, St. Louis, MO, USA) and was carried out according to instructions from the manufacturer.
Isolation of intact mitochondria. Cells were harvested and washed once with ice-cold 1 Â PBS and spun down by centrifugation at 1200 r.p.m. for 5 min at 41C. The pellet was resuspended in 10 volumes of extraction buffer (200 mM mannitol, 68 mM sucrose, 50 mM Pipes-KOH pH 7.4, 50 mM KCL, 5 mM EGTA, 2 mM MgCl 2 , 1 mM DTT) containing various protease inhibitors (1 mM PMSF, 10 mg/ml aprotinin, 20 mg/ml pepstatin A and 10 mg/ml leupeptin) and incubated on ice for 20 min. After incubation, the cells were homogenized with a dounce homogenizer and passaged for 30 strokes before being centrifuged at 2000 g for 3 min at 41C. Thereafter, the supernatant was centrifuged again at 13000 g for 10 min at 41C as described elsewhere. 33 The pellet contains the intact mitochondria fraction. To obtain mitochondria devoid of the outer mitochondrial membrane, purified mitochondria were treated with 20 mg/ml proteinase K for 25 min on ice. Phenylmethylsulfonyl fluoride was then added to a final concentration of 2 mM and the samples were further incubated for another 10 min on ice as described elsewhere. 33, 34 The samples were subjected to centrifugation as described before to obtain isolated mitochondria. A second protocol for the isolation of mitochondria was also performed as described previously to validate our results obtained from the first technique. 26 Complex I, II, II-III and citrate synthase activity measurements. Complex I activity was determined using the Complex I Enzyme Activity Microplate Assay Kit (MitoSciences) on the basis of recommended protocol and settings described by the manufacturer. Complex II and II-III activity was quantified on the basis of established protocols described in previous studies. 35, 36 Citrate synthase activity was measured using the citrate synthase assay kit (Sigma-Aldrich) and was carried out according to instructions from the vendor.
COX isolation and activity. Cells were dissolved in 2 ml of COX buffer (250 mM sucrose, 2 mM HEPES and 0.1 mM EGTA at pH 7.4) before being centrifuged at 330 Â g for 10 min at 41C. The cells were then resuspended with 1 ml of COX buffer and incubated for 10 min at 41C before being subjected to homogenization for 10 passages; thereafter, the cell lysate was spun at 600 Â g for 10 min at 41C. The supernatant was then centrifuged at 14 400 Â g for 10 min at 41C. The resultant pellet is the purified mitochondria fraction, containing COX. The pellet was dissolved in 100 ml of prewarmed potassium phosphate buffer at pH 7.2 and was incubated at RT for 3 min. COX activity was measured by monitoring the oxidation of reduced cytochrome c by spectrophotometric analysis at 550 nm for 2 min at 371C using a BioSpec-1601 spectrophotometer (Shimadzu, Kyoto, Japan). COX activity was determined by measuring the decrease in absorbance of ferrocytochrome c caused by its oxidation to ferricytochrome c by COX.
Transient transfection. Transient transfection of CEM/Neo cells was performed using SuperFect Transfection Reagent from QIAGEN GmbH (Hilden, Germany). Briefly, 3 mg of pIRES (empty vector), pcDNA3-Bcl-2 or mutant Bcl-2 plasmids was added to 20 ml of the SuperFect Transfection Reagent and transfection was carried out as recommended by the vendor. Bcl-2 expression was detected from cell lysates at various posttransfection time points by western blotting using a primary mouse monoclonal anti-Bcl-2 antibody at 1 : 1000 dilution (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a secondary HRP-conjugated goat anti-mouse IgG at 1 : 5000 dilution (Pierce, Illinois, IL, USA).
RNA interference. CEM/Bcl-2 cells were transfected 48 h and 72 h before experiments with 0.2 mM Bcl-2-specific siRNA (QIAGEN GmbH, Germany) or scrambled siRNA duplexes using Oligofectamine reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The expression level of Bcl-2 was confirmed by western blotting using antibodies as described previously for the detection of Bcl-2.
O 2
À measurement by lucigenin. A lucigenin-based chemiluminescence assay was used for measuring intracellular O 2 À as described previously.
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Chemiluminescence was monitored using a Berthold Sirius Luminometer (Berthold detection systems GmbH, Bleichstrabe, Pforzheim, Germany). The assay was also used to detect the O 2 À level in isolated mitochondria in some instances. Data are described as RLUs/s per mg of protein.
O 2
À measurement by MitoSOX Red. The O 2 À production from mitochondria was also specifically monitored by MitoSOX Red (Invitrogen), which is a fluorescent probe targeted to the mitochondria and highly susceptible to oxidation by O 2 À . Briefly, 1 Â 10 6 cells were incubated with 10 mM MitoSOX Red reagent for 15 min at 371C. The cells were washed twice with 1 Â PBS and immediately analyzed in Epic Profile flow cytometer (Beckman Coulter Inc., Fullerton, CA, USA) with excitation set at 510 nm. Data were analyzed for 10 000 events using WinMDI software (http://facs.scripps.edu/software.html).
Mitochondrial transmembrane potential determination. Potentialsensitive probe 3,3 0 dihexyloxacarbocyanine iodide (DiOC 6 ) was used to measure mitochondrial transmembrane potential as described previously. 37 Briefly, 1 Â 10 6 cells were incubated with 40 nM DiOC 6 for 15 min at 371C. At least 10 000 events were analyzed by flow cytometry with excitation set at 488 nm.
Coimmunofluorescence using confocal microscopy. The cells were incubated for 1 h at RT. Thereafter, the cells were washed thrice with PBS to remove excess antibodies before being added to secondary antibodies conjugated with either Rhodamine Red (Molecular Probes, Invitrogen, Carlsbad, CA, USA) or FITC (Dako, Glostrup, Denmark) at 1 : 1000 or 1 : 50 dilution, respectively. The cells were incubated for 1 h at RT and washed thrice with PBS to remove excess antibodies. Each sample was then mounted onto a microscope glass slide (Livingstone, Rosbery, New South Wales, Australia) with 10 ml of FluorSave Reagent (Calbiochem, Merck KGaA, Darmstadt, Germany). The fluorochromes were subjected to excitation wavelengths of 488 nm at 1 mW HeNe Green and 543 nm at 40 mW argon for FITC and Rhodamine Red, respectively, using an Olympus IX81 FluoView 500 confocal microscope (Hamburg, Germany).
Coimmunoprecipitation and western blotting. Cells were lysed with 2 ml co-IP buffer (1% (v/v) NP40, 50 mM Tris, 150 mM NaCl at pH 7.4) and incubated on ice for 30 min with occasional mixing. The lysate was then centrifuged at 10 000 Â g for 10 min at 41C. Protein determination assay was carried out. An equal amount of protein was used for each sample, which was then added with BSA to reduce nonspecific binding, and subsequently added with 2 mg antibody targeting the bait. The samples were incubated overnight at 41C with rocking. Thereafter, 30 ml of Protein A-Agarose beads was added (Santa Cruz Biotechnology) and incubated for 2 h at 41C. The samples were centrifuged at 10 000 Â g for 75 s at 41C and the beads were washed with 1 ml co-IP buffer and centrifuged as described previously. Washing was repeated thrice. The pull-down fractions were then added with 40 ml of loading buffer. Proteins were analyzed and resolved on a 12% (v/v) acrylamide resolving gel, subjected to SDS-PAGE. The resolved proteins were then transferred onto a polyvinyl difluoride membrane by the semi-dry transfer method using the Hoefer TE 77 semi-dry transfer unit (Amersham Biosciences, Piscataway, NJ, USA). The membrane was subsequently blocked with 5% (w/v) fat-free milk in Tris-buffered saline containing 0.05% (v/v) Tween 20 (TBST) for 1 h. After three washes with TBST to remove excess milk, the membrane was probed for the protein of interest with the relevant primary antibody in 5% (w/v) BSA in TBST at 41C for 1-2 h. The membrane was subsequently subjected to three washes with TBST to remove unbound primary antibody and probed again with the appropriate HRPconjugated secondary antibody in TBST containing 1% (w/v) fat-free milk for 1 h at RT. After three washes with TBST to remove any excess unbound secondary antibody, the desired proteins were detected with a Kodak Biomax MR X-ray film (Sigma-Aldrich) by enhanced chemiluminescence using the SuperSignal Chemiluminescent Substrate (Pierce). The primary and secondary antibodies used for detection by western blot analysis were applied at 1 : 1000 and 1 : 5000 dilutions, respectively.
Blue Native PAGE. For immunoblot analysis of one-dimensional native gels, mitochondrial fractions were solubilized with n-dodecyl-b-D-maltoside or digitonin found in the NativePAGE Sample Prep Kit (Invitrogen) and carried out as described by the vendor and subsequently resolved on blue native 4-16% Bis-Tris polyacrylamide gels (Invitrogen). Electroblotting and immunodetection were routinely performed as described earlier.
Bioinformatics and mutagenesis. Structural homology analysis was carried out using the DaliLite server available on the web. Mutagenesis of bcl-2 was performed using the Quikchange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Point mutants and the domain mutant of Bcl-2 were generated as recommended by the vendor. Briefly, forward and reverse primers harboring the sequence for the respective point mutation were generated. Using the nonstranddisplacing action of PfuTurbo DNA polymerase, these mutagenic primers were then used in a PCR reaction, together with the plasmid containing the target gene and the intended site of mutation. The methylated, nonmutated parental DNA template was subsequently digested with Dpn I, leaving behind the daughter plasmid incorporated with the desired mutation of the target gene. Mutations were confirmed by sequencing, after transformation, selection and restriction digest.
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